S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
How to Find Penny Stocks to Invest and Trade
What Tyson Foods Q1 Means For Staples Stocks
A gold storm is coming… (Ad)
ONSemi Is Marching Higher On Great Results
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
How to Find Penny Stocks to Invest and Trade
What Tyson Foods Q1 Means For Staples Stocks
A gold storm is coming… (Ad)
ONSemi Is Marching Higher On Great Results
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
How to Find Penny Stocks to Invest and Trade
What Tyson Foods Q1 Means For Staples Stocks
A gold storm is coming… (Ad)
ONSemi Is Marching Higher On Great Results
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
How to Find Penny Stocks to Invest and Trade
What Tyson Foods Q1 Means For Staples Stocks
A gold storm is coming… (Ad)
ONSemi Is Marching Higher On Great Results
Can Cummins Power To A New High? 
NASDAQ:AVEO

AVEO Pharmaceuticals - AVEO Stock Forecast, Price & News

$15.00
0.00 (0.00%)
(As of 01/19/2023)
Add
Compare
Today's Range
$14.99
$15.00
50-Day Range
$14.87
$15.00
52-Week Range
$3.06
$15.00
Volume
247,800 shs
Average Volume
601,442 shs
Market Capitalization
$521.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

AVEO Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
N/A
Short Interest
Healthy
2.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of AVEO Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.68) to $0.52 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.33 out of 5 stars

Medical Sector

974th out of 1,027 stocks

Pharmaceutical Preparations Industry

474th out of 500 stocks

AVEO stock logo

About AVEO Pharmaceuticals (NASDAQ:AVEO) Stock

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Inhibrx (INBX) Down on Updated Data From Bone Cancer Study
AVEO Oncology Reports Third Quarter 2022 Financial Results
JonesTrading Reaffirms Their Hold Rating on AVEO Pharma (AVEO)
LG Chem to acquire AVEO Oncology for $566 million
Did These 6 Biotech Stocks Catch Your Eye?
See More Headlines
Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Company Calendar

Last Earnings
11/08/2021
Today
2/07/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AVEO
CUSIP
05358810
Employees
114
Year Founded
2001

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-53,340,000.00
Pretax Margin
-30.79%

Debt

Sales & Book Value

Annual Sales
$42.29 million
Book Value
$1.33 per share

Miscellaneous

Free Float
33,619,000
Market Cap
$521.45 million
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Michael P. BaileyMichael P. Bailey
    President, Chief Executive Officer & Director
  • Jebediah Ledell
    Chief Operating Officer
  • Erick J. Lucera
    Chief Financial Officer
  • Matthew Coulter
    Vice President-Information Technology
  • Stefanie Solomon
    Head-Compliance













AVEO Stock - Frequently Asked Questions

Should I buy or sell AVEO Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AVEO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVEO, but not buy additional shares or sell existing shares.
View AVEO analyst ratings
or view top-rated stocks.

What is AVEO Pharmaceuticals' stock price forecast for 2023?

5 analysts have issued 1 year price targets for AVEO Pharmaceuticals' stock. Their AVEO share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next year.
View analysts price targets for AVEO
or view top-rated stocks among Wall Street analysts.

How have AVEO shares performed in 2023?

AVEO Pharmaceuticals' stock was trading at $14.95 at the start of the year. Since then, AVEO stock has increased by 0.3% and is now trading at $15.00.
View the best growth stocks for 2023 here
.

When is AVEO Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our AVEO earnings forecast
.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to analyst estimates of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same period in the previous year, the company earned ($0.33) earnings per share.

When did AVEO Pharmaceuticals' stock split?

AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Trium Capital LLP (0.35%), Birchview Capital LP (0.29%), Wolverine Asset Management LLC (0.06%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends
.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $15.00.

How much money does AVEO Pharmaceuticals make?

AVEO Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $521.45 million and generates $42.29 million in revenue each year. The biopharmaceutical company earns $-53,340,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does AVEO Pharmaceuticals have?

The company employs 114 workers across the globe.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The official website for the company is www.aveooncology.com. The biopharmaceutical company can be reached via phone at (617) 400-0101, via email at ir@aveooncology.com, or via fax at 617-995-4995.

This page (NASDAQ:AVEO) was last updated on 2/7/2023 by MarketBeat.com Staff